Johnson & Johnson misses revenue estimates on flat sales of blockbuster drug

Stelara sales were flat at $2.45bn, falling short of analysts' expectations of $2.6bn.

Stelara sales were flat at $2.45bn, falling short of analysts' expectations of $2.6bn.

Johnson & Johnson's first quarter revenue missed analysts' estimates, with sales of its blockbuster psoriasis drug Stelara coming in lower than expected as the company prepares for its loss of exclusivity in the US.

Stelara sales were flat at $2.45bn, falling short of analysts' expectations of $2.6bn. J&J chief financial officer Joe Wolk said Stelara revenue was flat because of contracting with healthcare providers and pharmacy benefit managers in anticipation of the drug's loss of exclusivity in the US next year. 

You have reached your article limit. Already a subscriber? Sign in

BLACK FRIDAY

Offer ends in:

Days
0
Hours
0
Minutes
0
Seconds
0
Black Friday subscription offer

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited